News ArticleSyngene International Q2 FY27 Revenue Rises to Rs 833 Crore with New Biologics Manufacturing Contract and Enhanced Drug Discovery Capabilities
Company commissions Clinical Translational Sciences lab and expands digital research capabilities; plans Bayview Biologics manufacturing to begin next year
Syngene International Limited reported its Q2 FY27 results with revenue from operations at Rs 833 crore, marking a 13% quarter-on-quarter growth. The company advanced its integrated drug discovery services and signed its first manufacturing agreement for the Bayview biologics facility, planning drug-substance manufacturing to start next year.
Syngene International Limited
Investor Presentation
Syngene International Limited reported Q2 FY27 revenue of Rs 833 crore, up 13% from the previous quarter, driven by new contracts in biologics manufacturing and advances in integrated drug discovery services.
The company strengthened its integrated drug discovery offering by unifying Chemistry, Biology, and Biotherapeutics under the leadership of Chief Scientific Officer Dr. Jayashree Aiyar.
Syngene signed its first manufacturing agreement for the Bayview biologics facility with a large pharmaceutical customer, marking a key milestone. Process development is set to begin in India this year, followed by drug-substance manufacturing at Bayview next year, supporting its India-U.S. delivery model.
Additional manufacturing contracts were secured, including clinical material supply agreements from its Bengaluru biologics facility (Unit 3), indicating growing customer traction and a broader manufacturing pipeline.
Syngene commissioned a Clinical Translational Sciences laboratory in Bengaluru integrating clinical biomarker development, biobanking, patient stratification, precision medicine, and bioanalytical capabilities, enhancing connectivity across the drug development continuum.
The company expanded its digital capabilities with ChemVoyager, automated analytical systems, and end-to-end sample tracking, improving research workflow efficiency and data management.
Highlights
- Q2 FY27 revenue from operations reached Rs 833 crore, up 13% quarter-on-quarter and down 9% year-on-year.
- Operating EBITDA margin was 18%, impacted by lower revenues and forex hedge losses; adjusted margins are in the mid-20% range.
- Pat before exceptional items was Rs 38 crore in Q2 FY27, compared with Rs 1 crore in Q1 FY27.
- First manufacturing agreement signed for Bayview Biologics Facility; process development to start in India in 2026, manufacturing planned for 2027.
- Clinical Translational Sciences laboratory commissioned in Bengaluru to enhance translational research and precision medicine capabilities.
- Cost optimization initiatives completed on manpower, with other initiatives ongoing to improve operational efficiency.
Key Data Snapshot
What happened
- Syngene International reported Q2 FY27 revenue of Rs 833 crore with positive sequential growth.
- The company signed its first manufacturing agreement for the Bayview Biologics facility, advancing its large-molecule manufacturing capabilities.
- An integrated drug discovery service was enhanced under unified leadership of the Chief Scientific Officer.
- New contracts for clinical material manufacturing were secured at the Bengaluru biologics facility.
- A new Clinical Translational Sciences laboratory was commissioned to integrate discovery and development functions.
- Digital research capabilities were enhanced with new automated systems and software tools.
- Cost optimization initiatives focused on manpower have been implemented to improve competitiveness.
Key details
- The Bayview Biologics facility process development is scheduled to start in India in 2026, with drug-substance manufacturing planned for 2027.
- Q2 FY27 operating EBITDA margin was 18%, affected by forex hedge losses; adjusted margin is in the mid-20% range.
- PAT before exceptional items was Rs 38 crore in Q2 FY27, compared with Rs 1 crore in Q1 FY27, indicating improved profitability.
- Syngene's workforce includes approximately 5,700 scientists out of a total headcount of over 8,300.
- Syngene operates four global state-of-the-art campuses in Bangalore, Mangalore, Hyderabad, and Baltimore.
Strategic context
- Syngene is progressing in integrated drug discovery, development, and manufacturing services across small and large molecules.
- The company aims to strengthen India-U.S. delivery models with dual-continent supply capabilities.
- The commissioning of the Clinical Translational Sciences lab supports translational research, biomarker development and precision medicine.
- Digital upgrades like ChemVoyager and automated analytical systems enhance data-driven research workflows.
- Syngene continues to focus on cost management and operational efficiency to remain competitive in the global contract research and manufacturing industry.
Highlights
- Q2 FY27 revenue from operations reached Rs 833 crore, up 13% quarter-on-quarter and down 9% year-on-year.
- Operating EBITDA margin was 18%, impacted by lower revenues and forex hedge losses; adjusted margins are in the mid-20% range.
- Pat before exceptional items was Rs 38 crore in Q2 FY27, compared with Rs 1 crore in Q1 FY27.
- First manufacturing agreement signed for Bayview Biologics Facility; process development to start in India in 2026, manufacturing planned for 2027.
- Clinical Translational Sciences laboratory commissioned in Bengaluru to enhance translational research and precision medicine capabilities.
- Cost optimization initiatives completed on manpower, with other initiatives ongoing to improve operational efficiency.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
APAR Industries Reports Highest Ever Revenue and Announces Rs 1,500 Crore Capex for Financial Year 2027
APAR Industries Limited shared its October 2026 corporate presentation revealing its highest consolidated revenue to date for FY 2025-26 and outlining a robust Rs 1,500 crore capital expenditure plan for FY27 aimed at scaling operations and capturing emerging opportunities in the energy infrastructure sector.
Read Full Story
APAR Industries Posts Rs. 914.80 Crore Profit After Tax in H1 FY 2026-27, Approves USD 100 Million Investment in Singapore Subsidiary
APAR Industries Limited announced unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, posting a consolidated profit after tax of Rs. 914.80 crore for the half year of FY 2026-27.
Read Full Story
Schaeffler India Limited Shares Q3 CY26 Industry and Economic Highlights Showing Strong Automotive Sector Growth
Schaeffler India Limited disclosed its Q3 CY26 investor presentation detailing key economic indicators and industry sector performances including significant growth in automotive production volumes during the quarter.
Read Full Story
